JP2017516501A - 肺がんのタイピング法 - Google Patents

肺がんのタイピング法 Download PDF

Info

Publication number
JP2017516501A
JP2017516501A JP2017515878A JP2017515878A JP2017516501A JP 2017516501 A JP2017516501 A JP 2017516501A JP 2017515878 A JP2017515878 A JP 2017515878A JP 2017515878 A JP2017515878 A JP 2017515878A JP 2017516501 A JP2017516501 A JP 2017516501A
Authority
JP
Japan
Prior art keywords
biomarkers
classifier biomarkers
sample
classifier
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516501A5 (enExample
Inventor
ハワジン ファルキ，
ハワジン ファルキ，
マイラ ライ−ゴールドマン，
マイラ ライ−ゴールドマン，
チャールズ ペロウ，
チャールズ ペロウ，
デイビッド ニール ヘイズ，
デイビッド ニール ヘイズ，
グレッグ メイヒュー，
グレッグ メイヒュー，
チェン ファン，
チェン ファン，
マーク アール． ミグラリース，
マーク アール． ミグラリース，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2017516501A publication Critical patent/JP2017516501A/ja
Publication of JP2017516501A5 publication Critical patent/JP2017516501A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017515878A 2014-05-30 2015-06-01 肺がんのタイピング法 Pending JP2017516501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462005229P 2014-05-30 2014-05-30
US62/005,229 2014-05-30
PCT/US2015/033611 WO2015184461A1 (en) 2014-05-30 2015-06-01 Methods for typing of lung cancer

Publications (2)

Publication Number Publication Date
JP2017516501A true JP2017516501A (ja) 2017-06-22
JP2017516501A5 JP2017516501A5 (enExample) 2018-07-12

Family

ID=54699976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515878A Pending JP2017516501A (ja) 2014-05-30 2015-06-01 肺がんのタイピング法

Country Status (6)

Country Link
US (1) US10829819B2 (enExample)
EP (1) EP3149209B1 (enExample)
JP (1) JP2017516501A (enExample)
CN (1) CN107208131A (enExample)
CA (1) CA2950623A1 (enExample)
WO (1) WO2015184461A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849613A (zh) * 2015-04-14 2018-03-27 基因中心治疗公司 用于肺癌分型的方法
CA3024744A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
US10934595B2 (en) 2016-05-17 2021-03-02 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
WO2020076897A1 (en) * 2018-10-09 2020-04-16 Genecentric Therapeutics, Inc. Detecting cancer cell of origin
CN112375826B (zh) * 2020-12-03 2021-08-27 远见生物科技（上海）有限公司 一种鉴别非小细胞肺癌亚型的环状rna组合物标志物及其应用
CN113186287B (zh) * 2021-05-10 2023-03-24 深圳康华君泰生物科技有限公司 用于非小细胞肺癌分型的生物标志物及其应用
CN115851927A (zh) * 2022-08-09 2023-03-28 上海善准医疗科技有限公司 肺鳞癌分子分型及生存风险基因群及诊断产品和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151110A2 (en) * 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU2002226912A1 (en) * 2000-11-16 2002-05-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2008021115A2 (en) * 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
CN101914542B (zh) * 2009-04-28 2013-03-06 中国科学院化学研究所 用于不同亚型非小细胞肺癌分型的一种核酸适体及其筛选方法
WO2012131670A2 (en) * 2011-03-28 2012-10-04 Rosetta Genomics Ltd Methods for lung cancer clasification
WO2013172926A1 (en) 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
WO2013190090A1 (en) * 2012-06-21 2013-12-27 Philip Morris Products S.A. Gene signatures for classifying and grading lung cancer
CN107849613A (zh) 2015-04-14 2018-03-27 基因中心治疗公司 用于肺癌分型的方法
CA3024744A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
US10934595B2 (en) 2016-05-17 2021-03-02 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151110A2 (en) * 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF MOLECULAR DIAGNOSTICS, vol. 15, no. 4, JPN6019015024, 2013, pages 485 - 497, ISSN: 0004206603 *

Also Published As

Publication number Publication date
EP3149209A1 (en) 2017-04-05
CA2950623A1 (en) 2015-12-03
WO2015184461A1 (en) 2015-12-03
US20170114416A1 (en) 2017-04-27
CN107208131A (zh) 2017-09-26
US10829819B2 (en) 2020-11-10
EP3149209B1 (en) 2021-02-17
EP3149209A4 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
JP7241353B2 (ja) 肺腺癌のサブタイピングのための方法
JP7241352B2 (ja) 肺扁平上皮癌のサブタイピングのための方法
US20220243283A1 (en) Methods for typing of lung cancer
US11851715B2 (en) Detecting cancer cell of origin
JP2017516501A (ja) 肺がんのタイピング法
US20230395263A1 (en) Gene expression subtype analysis of head and neck squamous cell carcinoma for treatment management
US12006554B2 (en) Methods for subtyping of head and neck squamous cell carcinoma
US11739386B2 (en) Methods for determining response to PARP inhibitors
US12195805B2 (en) Methods for subtyping of bladder cancer
US20240182984A1 (en) Methods for assessing proliferation and anti-folate therapeutic response
WO2021262696A2 (en) Methods for selecting and treating cancer with fgfr3 inhibitors
WO2023164595A2 (en) Methods for subtyping and treatment of head and neck squamous cell carcinoma
WO2025259592A1 (en) Therapeutic predictive response signatures and uses thereof in cancer patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200204